Skip to main content

“Reaching a significant difference already in a small number of patients in this well-run exploratory trial gives a surprisingly clear positive signal in what could become a large new indication for RUCONEST®.”

- Prof Bruno Giannetti, Pharming’s COO
Cookies: This website uses cookies Check the cookies page for more information Accept Decline